Scotiabank raised the firm’s price target on Liquidia (LQDA) to $37 from $36 and keeps an Outperform rating on the shares. The firm is updating its model on the stock following Yutrepia’s approval and its expectations for early launch dynamics, the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LQDA:
- Buy Rating Affirmed for Liquidia Technologies: Yutrepia’s FDA Approval and Strategic Market Positioning Drive Confidence
- Liquidia price target raised to $35 from $29 at H.C. Wainwright
- Buy Rating for Liquidia Technologies Driven by FDA Approval and Strategic Launch of Yutrepia
- Liquidia price target raised to $23 from $20 at Wells Fargo
- Strategic Launch and Market Potential of Yutrepia Justifies Buy Rating for Liquidia Technologies
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue